natgillin/translations-raw huggingface dataset:
Limited experience from 150 pregnancy outcomes (primarily based on spontaneous reporting and literature review) is available suggesting that use of Cerezyme is beneficial to control the underlying Gaucher disease in pregnancy.
Postoji ograničeno iskustvo o ishodima 150 trudnoća (prvenstveno temeljeno na spontanom prijavljivanju i podacima iz literature) koje upućuje na to da primjena lijeka Cerezyme ima pozitivan učinak na kontrolu ranije dijagnosticirane Gaucherove bolesti tijekom trudnoće.
Contents of the pack and other information What Cerezyme contains
Sadržaj pakiranja i druge informacije Što Cerezyme sadrži
Clinically, Gaucher disease is a heterogeneous phenotypic spectrum.
Klinički, Gaucherova bolest ima heterogeni fenotipski spektar.
Store in a refrigerator (2°C - 8°C).
Čuvati u hladnjaku (2°C - 8°C)
It is recommended that the diluted solution be administered within 3 hours.
Razrijeđenu otopinu preporučuje se primijeniti unutar 3 sata.
Furthermore, these data indicate no malformative toxicity for the foetus by Cerezyme, although the statistical evidence is low.
Nadalje, ovi podaci ne upućuju na malformacijsku toksičnost lijeka Cerezyme na plod , iako su statistički dokazi koji to potvrđuju malobrojni.
Generally, improvements in organ systems with a faster turnover rate, such as the haematological, can be noted far more rapidly than in those with a slower turnover, such as the bone.
Općenito se poboljšanja u organskim sustavima u kojima se stanice brže obnavljaju, poput hematološkog sustava, može primijetiti mnogo prije nego u sustavima u kojima se stanice obnavljaju sporije, poput koštanog sustava.
If you experience any of these symptoms, please tell your doctor immediately.
Ako Vam se pojavi bilo koji od ovih simptoma, molimo odmah o tome obavijestite svog liječnika.
Pulmonary hypertension is a known complication of Gaucher disease.
Plućna hipertenzija je poznata komplikacija Gaucherove bolesti.
In Gaucher disease glucosylceramide levels can get too high.
Kod Gaucherove bolesti vrijednosti glukozilceramida mogu postati previsoke.
At subsequent administrations, infusion rate may be increased but should not exceed 1 unit per kg body weight per minute.
Tijekom kasnijih primjena, brzina infuzije može se povećati, ali ne smije premašiti 1 jedinicu po kilogramu tjelesne težine u minuti.
Gaucher disease is associated with increased morbidity and early mortality.
Gaucherova bolest povezana je s povećanim pobolom i ranom smrtnošću.
Instructions for proper use Cerezyme is given through a drip into a vein (by intravenous infusion).
Upute za ispravnu primjenu Cerezyme se primjenjuje kapanjem (dripom) u venu (intravenskom infuzijom).
The current medical standards for emergency treatment are to be observed.
Za hitno liječenje, treba slijediti postojeće medicinske standarde.
A Q4 infusion regimen may be a therapeutic option for some adult patients with stable residual Gaucher disease type 1, but clinical data are limited.
Režim primjene infuzije svaka 4 tjedna mogao bi predstavljati terapijsku opciju za neke odrasle bolesnike sa stabilnom rezidualnom Gaucherovom bolešću tipa 1, no klinički podaci su ograničeni.
Some side effects were seen primarily while patients were being given the medicine or shortly after.
Neke su se nuspojave pojavile prvenstveno tijekom primjene lijeka bolesnicima ili neposredno nakon toga.
Foetal demise has been reported rarely, although it is not clear whether this related to the use of Cerezyme or to the underlying Gaucher disease.
Rijetko je prijavljena smrt ploda, ali nije jasno je li ona povezana s primjenom lijeka Cerezyme ili s osnovnom Gaucherovom bolešću.
Urticaria/angioedema*, pruritus*, rash*
Urtikarija/angioedem*, pruritus*, osip*
It is recommended that Cerezyme is used immediately after it has been mixed with sterile water.
Preporučuje se primijeniti lijek Cerezyme odmah nakon miješanja sa sterilnom vodom.
The rate and extent of response to Cerezyme treatment is dose-dependent.
Brzina i opseg odgovora na liječenje lijekom Cerezyme ovisi o dozi.
During 1 hour intravenous infusions of 4 doses (7.5, 15, 30, 60 U/kg) of imiglucerase, steady-state enzymatic activity was achieved by 30 minutes.
Pri jednosatnim intravenskim infuzijama 4 doze (7,5, 15, 30, 60 U/kg) imigluceraze stanje dinamičke ravnoteže enzimske aktivnosti postignuto je nakon 30 minuta.
Cerezyme therapy reduces the requirement for splenectomy in most cases and early treatment with Cerezyme has been associated with a reduced risk of pulmonary hypertension.
Liječenje lijekom Cerezyme u većini slučajeva smanjuje potrebu za splenektomijom, a rano liječenje lijekom Cerezyme povezuje se sa smanjenim rizikom od razvoja plućne hipertenzije.
Patients who have developed antibodies or symptoms of hypersensitivity to Ceredase (alglucerase) should be treated with caution when administering Cerezyme (imiglucerase).
U bolesnika koji su razvili protutijela ili simptome preosjetljivosti na Ceredase (alglucerazu), Cerezyme (imigluceraza) se mora primjenjivati uz oprez.
Therefore no conclusions on the effect of enzyme replacement therapy on the neurological manifestations of the disease can be drawn.
Stoga se ne mogu donijeti zaključci o učinku enzimske nadomjesne terapije na neurološke manifestacije bolesti.
Instructions for use - reconstitution, dilution and administration Each vial of Cerezyme is for single use only.
Upute za uporabu - rekonstitucija, razrjeđivanje i primjena Jedna bočica lijeka Cerezyme namijenjena je isključivo za jednokratnu uporabu.
Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualization of dose according to the patient's needs and therapeutic response.
Nužno je pažljivo praćenje trudnoće i kliničkih manifestacija Gaucherove bolesti radi određivanja individualnih doza lijeka u skladu s potrebama i terapijskim odgovorom bolesnice.
If you forget to use Cerezyme
Ako ste zaboravili primijeniti lijek Cerezyme
It appears that patients who will develop IgG antibody are most likely to do so within 6 months of treatment and will rarely develop antibodies to Cerezyme after 12 months of therapy.
Čini se da bolesnici najčešće stvaraju IgG protutijela tijekom prvih 6 mjeseci liječenja, a rijetko stvaraju protutijela na Cerezyme nakon 12 mjeseci liječenja.
Dose and infusion rate should remain constant while at home, and not be changed without supervision of a health care professional.
Kad se infuzija primjenjuje kod kuće, doza i brzina moraju biti konstantne i ne smiju se mijenjati bez nadzora zdravstvenog djelatnika.
Talk to your doctor or pharmacist before using Cerezyme: - if you are treated with Cerezyme, you may experience an allergic reaction while you are being given the medicine or shortly after.
Obratite se svome liječniku ili ljekarniku prije nego primite Cerezyme: - ako se liječite lijekom Cerezyme, možete doživjeti alergijsku reakciju tijekom primjene lijeka ili neposredno nakon toga.
Rare (may affect up to 1 in 1,000 people): - anaphylactoid reactions
Rijetko (mogu se javiti u manje od 1 na 1000 osoba): - anafilaktoidne reakcije
Cerezyme has been shown to improve both mental and physical aspects in the quality of life of Gaucher disease.
Pokazalo se da Cerezyme poboljšava mentalne i fizičke aspekte kvalitete života bolesnika s Gaucherovom bolešću.
Pharmacotherapeutic group: Enzymes-Imiglucerase (recombinant macrophage targeted βglucocerebrosidase), ATC code: A16AB02.
Farmakoterapijska skupina: Enzimi - imigluceraza (rekombinantna β-glukocerebrozidaza koja ciljano djeluje na makrofage), ATK oznaka: A16AB02.
Plasma clearance ranged from 9.8 to 20.3 ml/min/kg, (mean ± S.D, 14.5 ± 4.0 ml/min/kg).
Klirens iz plazme se kretao u rasponu od 9,8 do 20,3 ml/min/kg, (srednja vrijednost ± SD, 14,5 ± 4,0 ml/min/kg).
The volume of distribution corrected for weight ranged from 0.09 to 0.15 l/kg (mean ± S.D 0.12 ± 0.02 l/kg).
Volumen distribucije korigiran za tjelesnu težinu bio je u rasponu od 0,09 do 0,15 l/kg (srednja vrijednost ± SD 0,12 ± 0,02 l/kg).
This enzyme helps the body control levels of glucosylceramide.
Taj enzim pomaže tijelu u kontroli razine glukozilceramida.
The clinical manifestations of Gaucher disease can adversely affect quality of life.
Gaucherove bolesti mogu loše utjecati na kvalitetu života.
Patients experiencing adverse events during the infusion need to immediately stop the infusion process and seek the attention of a healthcare professional.
Bolesnici u kojih tijekom primanja infuzije nastupe nuspojave, moraju odmah prekinuti infuziju i potražiti pomoć zdravstvenog djelatnika.
You can ask your doctor to register your patient information into the “ICGG Gaucher Registry”.
Možete zamoliti svoga liječnika da Vaše bolesničke podatke prijavi u “ICGG registar bolesnika s
Due to the heterogeneity and the multi-systemic nature of Gaucher disease, dosage should be individualised for each patient based on a comprehensive evaluation of all clinical manifestations of the disease.
Doziranje Zbog heterogenosti i multisistemske prirode Gaucherove bolesti, doziranje se mora prilagoditi svakom pojedinom bolesniku na temelju sveobuhvatne procjene svih kliničkih manifestacija bolesti.
There are no cases of overdose of Cerezyme reported.
Nema prijavljenih slučajeva predoziranja lijekom Cerezyme.
It is not known whether this active substance is excreted in human milk, however, the enzyme is likely to be digested in the child's gastrointestinal tract
Nije poznato izlučuje li se ova djelatna tvar u majčino mlijeko, ali se enzim vjerojatno probavlja u probavnom sustavu djeteta.
Glucosylceramide is a natural substance in the body, made of sugar and fat.
Glukozilceramid je prirodna tvar u ljudskome tijelu, a sačinjavaju je šećer i masnoća.
Your doctor may test if you have an allergic reaction to imiglucerase.
Liječnik Vas može poslati na pretrage kako bi ispitao imate li alergijsku reakciju na imiglucerazu.
- some patients with Gaucher disease have high blood pressure in the lungs (pulmonary hypertension).
- neki bolesnici s Gaucherovom bolešću imaju visok krvni tlak u plućima (plućnu hipertenziju).
In addition, Gaucher disease has been associated with an increased risk of immunoglobulin abnormalities such as hyperimmunoglobulinemia, polyclonal gammopathy, monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Nadalje, Gaucherova je bolest povezana s povećanim rizikom od poremećaja imunoglobulina, poput hiperimunoglobulinemije, poliklonske gamopatije, monoklonske gamopatije neodređenog značaja (engl. monoclonal gammopathy of undetermined significance,
In children, Cerezyme has been shown to enable normal pubertal development, and to induce catch-up growth, leading to normal height and bone mineral density in adulthood.
Pokazalo se da Cerezyme u djece omogućava normalan razvoj u pubertetu te nadoknađuje zastoj u rastu, što omogućuje postizanje normalne visine i mineralne gustoće kostiju u odrasloj dobi.
Patients who have Gaucher disease and become pregnant may experience a period of increased disease activity during pregnancy and the puerperium.
Bolesnice s Gaucherovom bolešću koje zatrudne mogu proći kroz razdoblje pojačane aktivnosti bolesti tijekom trudnoće i puerperija.
Cerezyme is an artificial enzyme called imiglucerase - this can replace the natural enzyme acid β-glucosidase which is lacking or not active enough in patients with Gaucher disease.
Cerezyme je umjetni enzim koji se naziva imigluceraza - on može nadomjestiti prirodni enzim kiselu β-glukozidazu koja nedostaje ili nije dovoljno aktivna u bolesnika s Gaucherovom bolešću.
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.
Cerezyme (imigluceraza) je indiciran kao dugotrajna enzimska nadomjesna terapija u bolesnika s potvrđenom dijagnozom neneuropatske (tip 1) ili kronične neuropatske (tip 3) Gaucherove bolesti koji pokazuju klinički značajne manifestacije bolesti koje nisu neurološke naravi.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL / VIAL
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA / BOČICA
Cerezyme reduces spleen and liver size, improves or normalises thrombocytopenia and anaemia, improves or normalises bone mineral density and bone marrow burden, and reduces or eliminates bone pain and bone crises.
Cerezyme smanjuje veličinu slezene i jetre, poboljšava ili normalizira trombocitopeniju i anemiju, poboljšava ili normalizira mineralnu gustoću kostiju i opterećenje koštane srži te smanjuje ili uklanja bol u kostima i koštane krize.
Patients treated with 60 U/kg body weight every 2 weeks showed a faster improvement and a greater maximum treatment effect as compared to patients receiving the lower doses.
U bolesnika liječenih dozom od 60 U/kg tjelesne težine jedanput svaka 2 tjedna zabilježeno je brže poboljšanje i veći maksimalni učinak liječenja u usporedbi s bolesnicima koji su primali niže doze.
In women receiving Cerezyme treatment continuation throughout pregnancy should be considered.
U žena koje se liječe lijekom Cerezyme treba razmotriti nastavak liječenja tijekom trudnoće.
Gaucher cells are typically found in liver, spleen and bone marrow and occasionally in lung, kidney and intestine.
Gaucherove stanice se obično nalaze u jetri, slezeni i koštanoj srži, a ponekad i u plućima, bubrezima i crijevima.
If a patient experiences a reaction suggestive of hypersensitivity, subsequent testing for imiglucerase antibodies is advised.
Ako se u bolesnika pojavi reakcija koja upućuje na preosjetljivost, preporučuje se testiranje na protutijela na imiglucerazu.
If you experience a reaction like this, you should tell your doctor immediately.
Ako dođe do takve reakcije, odmah o tome obavijestite svog liječnika.
Then dilute the combined volumes with 0.9% sodium chloride intravenous solution to a total volume of 100 to 200 ml.
Zatim tako dobiveni volumen otopine razrijedite s 0,9%-tnom otopinom natrijevog klorida za intravensku primjenu do ukupnog volumena od 100 do 200 ml.
This enzyme breaks down glucosylceramide, a key component of the lipid structure of cell membranes, into glucose and ceramide.
Ovaj enzim razgrađuje glukozilceramid, ključnu komponentu u lipidnoj strukturi stanične membrane, u glukozu i ceramid.
If these reactions occur, immediate discontinuation of the Cerezyme infusion is recommended and appropriate medical treatment should be initiated.
preporučuje se odmah prekinuti infuziju lijeka Cerezyme i započeti odgovarajuće liječenje.
In children, Gaucher disease can lead to growth retardation and delayed puberty.
U djece Gaucherova bolest može dovesti do zastoja u rastu i zakašnjelog puberteta.
Patients who have undergone a splenectomy have an increased risk of pulmonary hypertension.
U bolesnika koji su bili podvrgnuti splenektomiji postoji povećan rizik od razvoja plućne hipertenzije.
No controlled clinical studies have been conducted on the efficacy of Cerezyme on neurological manifestations of the disease.
Nisu provedena kontrolirana klinička ispitivanja djelotvornosti lijeka Cerezyme na neurološke manifestacije bolesti.
Current data using a screening ELISA followed by a confirmatory radioimmunoprecipitation assay, suggest that, during the first year of therapy, IgG antibodies to imiglucerase are formed in approximately 15% of the treated patients.
Preosjetljivost Postojeći podaci dobiveni probirom ELISA testom i potvrđeni radioimunoprecipitacijskim testom upućuju na to da se tijekom prve godine liječenja u približno 15% liječenih bolesnika stvaraju
Name and address of the manufacturer of the biological active substance Genzyme Corporation, 500 Soldiers Field Road, Allston, MA 02134, USA Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, USA Name and address of the manufacturers responsible for batch release Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Genzyme Corporation, 500 Soldiers Field Road, Allston, MA 02134, SAD Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, SAD Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Ujedinjeno Kraljevstvo Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska
Imiglucerase is a modified form of the human enzyme acid β-glucosidase produced by recombinant DNA technology.
Imigluceraza je modificirani oblik ljudskog enzima kisele β-glukozidaze koja se proizvodi tehnologijom rekombinantne DNK.
Cerezyme reduces resting energy expenditure rate.
Cerezyme smanjuje potrošnju energije u mirovanju.
At initial infusions, Cerezyme should be administered at a rate not exceeding 0.5 unit per kg body weight per minute.
Tijekom početnih infuzija Cerezyme se mora primjenjivati brzinom od najviše 0,5 jedinica po kilogramu tjelesne težine u minuti.
What you need to know before you are given Cerezyme Do not use Cerezyme
Što morate znati prije nego primite Cerezyme Nemojte primjenjivati Cerezyme
Administration of doses as low as 15 U/kg of body weight once every 2 weeks has been shown to improve haematological parameters and organomegaly, but not bone parameters.
Primjena malih doza od 15 U/kg tjelesne težine jedanput svaka 2 tjedna dovela je do poboljšanja hematoloških vrijednosti i organomegalije, no ne i koštanih parametara.
This includes an increased risk of skeletal manifestations, exacerbation of cytopenia, haemorrhage, and an increased need for transfusion.
To uključuje povećani rizik od manifestacija na kostima, egzacerbacije citopenije, krvarenja te povećanu potrebu za transfuzijom.
Both pregnancy and lactation are known to stress maternal calcium homeostasis and to accelerate bone turnover.
Poznato je da razdoblja trudnoće i laktacije predstavljaju opterećenje za homeostazu kalcija i ubrzavaju koštanu pregradnju u majke.
Cautious use of Cerezyme during pregnancy and breastfeeding is recommended.
Preporučuje se oprez kod primjene lijeka Cerezyme za vrijeme trudnoće i dojenja.
Tachycardia*, cyanosis*
Tahikardija*, cijanoza*
In an ICGG Gaucher Registry analysis of a large cohort of patients (n=528) with Gaucher disease type 1, a time- and dose-dependent effect for Cerezyme was observed for haematological and visceral parameters (platelet count, haemoglobin concentration, spleen and liver volume) within the dose range of 15, 30 and 60 U/kg body weight once every 2 weeks.
International Collaborative Gaucher Group (ICGG) Gaucher Registry) provedenoj na velikoj kohorti bolesnika (n=528) s Gaucherovom bolešću tipa 1 zabilježeni su o vremenu i dozi ovisni učinci lijeka Cerezyme na hematološke i visceralne parametre (broj trombocita, koncentracija hemoglobina, volumen slezene i jetre) u rasponu doza od 15, 30 i 60 U/kg tjelesne težine jedanput svaka 2 tjedna.
In individuals with Gaucher disease, glucosylceramide degradation is insufficient, leading to accumulation of large quantities of this substrate within the lysosomes of macrophages (termed ‘Gaucher cells'), leading to widespread secondary pathology.
U osoba s Gaucherovom bolešću razgradnja glukozilceramida je nedostatna te dolazi do nakupljanja velike količine tog supstrata u lizosomima makrofaga (nazvanih "Gaucherove stanice"), što dovodi do rasprostranjene sekundarne patologije.
This should lead to improvement in the safe and effective use of Cerezyme.
Time bi se trebala povećati sigurnost i učinkovitost primjene lijeka Cerezyme.
People with Gaucher disease have low levels of an enzyme called acid β-glucosidase.
Osobe s Gaucherovom bolešću imaju niske razine enzima koji se zove kisela β-glukozidaza.
Imiglucerase (recombinant macrophage targeted acid ß-glucosidase) replaces the deficient enzyme activity, hydrolysing glucosylceramide, thus correcting initial pathophysiology and preventing secondary pathology.
Imigluceraza (rekombinantna kisela β-glukozidaza koja ciljano djeluje na makrofage) nadomješta nedostatnu enzimsku aktivnost tako što hidrolizira glukozilceramid i tako korigira početnu patofiziologiju i sprječava sekundarnu patologiju.
Routine evaluation to detect the presence of pulmonary hypertension after diagnosis of Gaucher disease and over time is recommended.
Preporučuje se rutinska obrada radi utvrđivanja plućne hipertenzije po dijagnosticiranju Gaucherove bolesti i povremeno tijekom bolesti.
Dizziness, headache, paraesthesia*
Omaglica, glavobolja, parestezija*
Cerezyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Gaucher disease.
Cerezyme se smije primjenjivati samo pod nadzorom liječnika s iskustvom u liječenju Gaucherove bolesti.
Gaucher disease is associated with increased glucose production and increased resting energy expenditure rate, which may contribute to fatigue and cachexia.
Gaucherova bolest povezana je s povećanom proizvodnjom glukoze te povećanom potrošnjom energije u stanju mirovanja, što može pridonijeti pojavi umora i kaheksije.
Pack sizes: 1, 5 or 25 vials per carton.
Veličine pakiranja: 1, 5 ili 25 bočica u kutiji.
The objectives of the “ICGG Gaucher Registry” are to enhance the understanding of Gaucher disease and to evaluate the effectiveness of enzyme replacement therapy, ultimately leading to improvement in the safe and efficacious use of Cerezyme.
Cilj “ICGG registra bolesnika s Gaucherovom bolešću” je pridonijeti razumijevanju Gaucherove bolesti i ocijeniti učinkovitost enzimske nadomjesne terapije, što će naposlijetku dovesti do sigurnije i djelotvornije primjene lijeka Cerezymee.
Treatment naïve women should be advised to consider commencing therapy prior to conception in order to attain optimal health.
Ženama koje nikad nisu bile liječene ovim lijekom treba preporučiti da s liječenjem započnu prije začeća kako bi postigle optimalno zdravstveno stanje.
Infusion of Cerezyme by the patient or caregiver at home requires training by a health care professional in a clinical setting.
Za primjenu infuzije lijeka Cerezyme kod kuće bolesnik ili njegovatelj moraju prethodno proći obuku koju u kliničkom okruženju provodi zdravstveni djelatnik.
Mix the infusion solution gently.
Otopinu za infuziju lagano promiješajte.
But, if you suffer with any shortness of breath you should tell your doctor.
Međutim, ako patite od nedostatka zraka, o tome morate obavijestiti svoga liječnika.
These skeletal manifestations include bone marrow infiltration, osteonecrosis, bone pain and bone crises, osteopenia and osteoporosis, pathological fractures, and growth impairment.
Koštane manifestacije uključuju infiltraciju koštane srži, osteonekrozu, bol u kostima i koštane krize, osteopeniju i osteoporozu, patološke prijelome i zastoj rasta.
Cerezyme contains the active substance imiglucerase and is used to treat patients who have a confirmed diagnosis of Type I or Type 3 Gaucher disease, who show signs of the disease such as: anaemia (low number of red blood cells), a tendency to bleed easily (due to low numbers of plateletsa type of blood cell), spleen or liver enlargement or bone disease.
Cerezyme sadrži djelatnu tvar imiglucerazu i primjenjuje se u liječenju bolesnika s potvrđenom dijagnozom Gaucherove bolesti tipa 1 ili tipa 3 koji pokazuju znakove bolesti kao što su: anemija (mali broj crvenih krvnih stanica), sklonost krvarenju (zbog malog broja trombocita - vrste krvnih stanica), povećanje slezene ili jetre te koštane bolesti.
The aims of this Registry are to increase the understanding of Gaucher disease and to check how well enzyme replacement therapy, like Cerezyme, works.
Ciljevi toga registra su unaprijediti razumijevanje Gaucherove bolesti i ocijeniti učinkovitost enzimske nadomjesne terapije kao što je lijek Cerezyme.
Cerezyme is supplied in type I borosilicate (clear) glass 20 ml vials.
Cerezyme je dostupan u bočicama od 20 ml od borosilikatnog (prozirnog) stakla tipa I.